E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Kothandaraman, Narasimhan ^a   Bajic, Vladimir B ^b   Brendan, Pang N K ^c   Chan, Yiong Huak ^a   Keow, Peh B ^c   Razvi, Khalil ^d,e   Salto Tellez, Manuel ^c   Choolani, Mahesh ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d Department of Oncology   (United Kingdom)

^e BASILDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; TRANSCRIPTION FACTOR E2F5; E2F5 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; HYPOTHESIS; MAJOR CLINICAL STUDY; OVARY CANCER; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; WESTERN BLOTTING; ALGORITHM; BIOSYNTHESIS; DISEASE COURSE; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; MIDDLE AGED; OVARY TUMOR; PHYSIOLOGY; REPRODUCIBILITY;

ADULT; AGED; ALGORITHMS; CA-125 ANTIGEN; DISEASE PROGRESSION; E2F5 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77950529299     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-64     Document Type: Article

References (57)

1. Bristow RE, Berek JS. Surgery for ovarian cancer: how to improve survival. Lancet 2006, 367(9522):1558-1560. 10.1016/S0140-6736(06)68671-6, 16698396.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
3. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000, 19(1):3-10. 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S, 10883018.
4. Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet 1997, 349(9045):113-117. 10.1016/S0140-6736(96)06071-0, 8996432.
5. Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1998, 13(4):179-187.
6. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009, 113(4):775-782.
7. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009, 10(4):327-340. 10.1016/S1470-2045(09)70026-9, 19282241.
8. Liu Y, Ganesan TS. Tumour suppressor genes in sporadic epithelial ovarian cancer. Reproduction 2002, 123(3):341-353. 10.1530/rep.0.1230341, 11882011.
9. Fehrmann RS, Li XY, Zee AG, de Jong S, Te Meerman GJ, de Vries EG, Crijns AP. Profiling studies in ovarian cancer: a review. Oncologist 2007, 12(8):960-966. 10.1634/theoncologist.12-8-960, 17766655.
10. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004, 10(10):3291-3300. 10.1158/1078-0432.CCR-03-0409, 15161682.
11. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001, 93(19):1458-1464. 10.1093/jnci/93.19.1458, 11584061.
12. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, Morin PJ. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000, 60(22):6281-6287.
13. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001, 98(3):1176-1181. 10.1073/pnas.98.3.1176, 14728, 11158614.
14. Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C, Okamoto A, Ochiai K, Takagi T, Nakamura Y. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000, 60(18):5007-5011.
15. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 287(13):1671-1679. 10.1001/jama.287.13.1671, 11926891.
16. Suzuki M, Kobayashi H, Tanaka Y, Hirashima Y, Kanayama N, Takei Y, Saga Y, Itoh H, Terao T. Bikunin target genes in ovarian cancer cells identified by microarray analysis. J Biol Chem 2003, 278(17):14640-14646. 10.1074/jbc.M300239200, 12571229.
17. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J, Boshoff C. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004, 90(3):686-692. 10.1038/sj.bjc.6601603, 2409606, 14760385.
18. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 2004, 10(13):4427-4436. 10.1158/1078-0432.CCR-04-0073, 15240533.
19. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004, 101(25):9309-9314. 10.1073/pnas.0401994101, 438973, 15184677.
20. Tchagang ABTA, DeRycke MS, Skubitz KM, Skubitz AP. Early detection of ovarian cancer using group biomarkers. Molecular Cancer Therapeutics 2008, 7(1):27-37. 10.1158/1535-7163.MCT-07-0565, 18187805.
21. Milde-Langosch K, Riethdorf S. Role of cell-cycle regulatory proteins in gynecological cancer. J Cell Physiol 2003, 196(2):224-244. 10.1002/jcp.10286, 12811815.
22. D'Andrilli G, Kumar C, Scambia G, Giordano A. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res 2004, 10(24):8132-8141. 10.1158/1078-0432.CCR-04-0886, 15623586.
23. Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de Vries EG, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 2009, 6(2):e24. 10.1371/journal.pmed.1000024, 2634794,2634794, 19192944.
24. Pipinikas CP, Nair SB, Kirby RS, Carter ND, Fenske CD. Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR: a preliminary study. Biomarkers 2007, 12(5):541-557. 10.1080/13547500701391353, 17701752.
25. Pipinikas CP, Carter ND, Corbishley CM, Fenske CD. HIF-1alpha mRNA gene expression levels in improved diagnosis of early stages of prostate cancer. Biomarkers 2008, 13(7):680-691. 10.1080/13547500802591992, 19096962.
26. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Kuo C, Wang HJ, Milford R, Morton DL, et al. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 2006, 12(4):1137-1143. 10.1158/1078-0432.CCR-05-1847, 16489066.
27. FIGO FIGO Cancer Committee. Staging announcement. Gynecol Oncol 1986, 25. FIGO.
28. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 2001, 61(15):5895-5904.
29. Bajic VB, Tan SL, Christoffels A, Schonbach C, Lipovich L, Yang L, Hofmann O, Kruger A, Hide W, Kai C, et al. Mice and men: their promoter properties. PLoS Genet 2006, 2(4):e54. 10.1371/journal.pgen.0020054, 1449896, 16683032.
30. Bajic VB, Choudhary V, Hock CK. Content analysis of the core promoter region of human genes. In Silico Biol 2004, 4(2):109-125.
31. Chong A, Zhang Z, Choi KP, Choudhary V, Djamgoz MB, Zhang G, Bajic VB. Promoter profiling and coexpression data analysis identifies 24 novel genes that are coregulated with AMPA receptor genes, GRIAs. Genomics 2007, 89(3):378-384. 10.1016/j.ygeno.2006.11.009, 17208408.
32. KWB CNV, Hall LO, Kegelmeyer WP. SMOTE: Synthetic Minority Over-sampling TEchnique. Journal of Articial Intelligence Research 2002, 16:37.
33. Cleary JGTL. An instance-based learner using an entropic distance measure. Proceedings of the 12th International Conference on Machine Learning 1995, 6.
34. Bajic VB. Comparing the success of different prediction software in sequence analysis: a review. Brief Bioinform 2000, 1(2):14.
35. Salto-Tellez M, Lee SC, Chiu LL, Lee CK, Yong MC, Koay ES. Microsatellite instability in colorectal cancer: considerations for molecular diagnosis and high-throughput screening of archival tissues. Clin Chem 2004, 50(6):1082-1086. 10.1373/clinchem.2003.030700, 15161730.
36. Ito QL K, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han TI HC, Ming T, Yeoh KG, Ito Y. Frequent cytoplasmic retention of RUNX3 in gastric cancer cells: A novel mechanism of inactivation. Cancer Research 2005, 65:7743-7750.
37. Apostolova MD, Ivanova IA, Dagnino C, D'Souza SJ, Dagnino L. Active nuclear import and export pathways regulate E2F-5 subcellular localization. J Biol Chem 2002, 277(37):34471-34479. 10.1074/jbc.M205827200, 12089160.
38. Croce MV, Isla-Larrain MT, Demichelis SO, Gori JR, Price MR, Segal-Eiras A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat 2003, 81(3):195-207. 10.1023/A:1026110417294, 14620915.
39. Clauss A, Lilja H, Lundwall A. The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun 2005, 333(2):383-389. 10.1016/j.bbrc.2005.05.125, 1939935, 15950183.
40. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003, 63(13):3695-3700.
41. Hanai J, Mammoto T, Seth P, Mori K, Karumanchi SA, Barasch J, Sukhatme VP. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem 2005, 280(14):13641-13647. 10.1074/jbc.M413047200, 15691834.
42. Linder S, Havelka AM, Ueno T, Shoshan MC. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 2004, 214(1):1-9. 10.1016/j.canlet.2004.06.032, 15331168.
43. Sheard MA, Vojtesek B, Simickova M, Valik D. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem 2002, 85(4):670-677. 10.1002/jcb.10173, 11968007.
44. Stigbrand T. The versatility of cytokeratins as tumor markers. Tumour Biol 2001, 22(1):1-3. 10.1159/000030148, 11054020.
45. Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, Lafitte JJ, Sculier JP. Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol 2006, 17(11):1673-1676. 10.1093/annonc/mdl287, 16980598.
46. Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Des 2005, 11(22):2873-2887. 10.2174/1381612054546699, 16101443.
47. Attwooll C, Lazzerini Denchi E, Helin K. The E2F family: specific functions and overlapping interests. EMBO J 2004, 23(24):4709-4716. 10.1038/sj.emboj.7600481, 535093, 15538380.
48. Chen C, Wells AD. Comparative analysis of E2F family member oncogenic activity. PLoS ONE 2007, 2(9):e912. 10.1371/journal.pone.0000912, 1975672, 17878947.
49. Sawiris GP, Sherman-Baust CA, Becker KG, Cheadle C, Teichberg D, Morin PJ. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 2002, 62(10):2923-2928.
50. Pierce AM, Schneider-Broussard R, Philhower JL, Johnson DG. Differential activities of E2F family members: unique functions in regulating transcription. Mol Carcinog 1998, 22(3):190-198. 10.1002/(SICI)1098-2744(199807)22:3<190::AID-MC7>3.0.CO;2-P, 9688145.
51. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U, Werner M. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med 2007, 85(3):293-304. 10.1007/s00109-006-0126-5, 17143621.
52. Polanowska J, Le Cam L, Orsetti B, Valles H, Fabbrizio E, Fajas L, Taviaux S, Theillet C, Sardet C. Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors. Genes Chromosomes Cancer 2000, 28(1):126-130. 10.1002/(SICI)1098-2264(200005)28:1<126::AID-GCC15>3.0.CO;2-G, 10738311.
53. Yu B, Lane ME, Wadler S. SU a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem Pharmacol 9516, 64(7):1091-1100.
54. Reimer D, Sadr S, Wiedemair A, Goebel G, Concin N, Hofstetter G, Marth C, Zeimet AG. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci 2006, 1091:270-281. 10.1196/annals.1378.073, 17341621.
55. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Muller-Holzner E, Marth C, Zeimet AG. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients. Clin Cancer Res 2007, 13(1):144-151. 10.1158/1078-0432.CCR-06-0780, 17200349.
56. Davidson B, Espina V, Steinberg SM, Florenes VA, Liotta LA, Kristensen GB, Trope CG, Berner A, Kohn EC. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 2006, 12(3 Pt 1):791-799. 10.1158/1078-0432.CCR-05-2516, 16467090.
57. Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, Sweep CG. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 2002, 21(55):8506-8509. 10.1038/sj.onc.1206040, 12466970.